In addition, we further identified eight genes among DEGs in risk subgroups as targets of drugs commonly used in MM through the DrugBank database: CYP2C19, CYP2C9, SLCO1A2, CYP17A1, CYP3A43, XDH, NOS1, and PTGS2 (Figure 9C). This evidence concerns the gene CYP17A1 and Miyoshi myopathy.